$BiondVax _老虎社区_美港股上老虎

2020-10-24

$BiondVax Pharmaceuticals Ltd.(BVXV)$BiondVax公布M-001通用流感疫苗候选药物3期临床试验结果

https://basic.10jqka.com.cn/ajax/usaph/pubDetail/bb6a82c9419cc29f_translation?supportzoom=true&client_userid=A2W2r&share_hxapp=gsc&share_action=&back_source=hyperlink

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

耐思
2020-10-24
耐思
以色列耶路撒冷-2020年10月23日-BiondVax Pharmaceuticals Ltd. （NASDAQ:BVXV）是一家开发通用流感疫苗的先驱，旨在提供针对当前、未来、季节性和大流行性流感的保护，今天公布了该公司作为独立的通用流感疫苗候选企业的关键的M-001三期临床试验的Topline数据。
耐思
2020-10-24
耐思
巴博科夫博士继续说， "我们已经开发了专门知识和知识产权来实现我们的目标，我们保留了一个最先进的制造设施。今后，我们将研究各种选择，以最大限度地提高这些资产的价值。
稳之道
2020-10-24
稳之道
已阅知，稳住就是

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":301297613,"tweetId":"301297613","gmtCreate":1603515198632,"gmtModify":1703830184741,"author":{"id":3564867055159291,"authorId":3564867055159291,"authorIdStr":"3564867055159291","name":"耐思","avatar":"https://static.tigerbbs.com/e3c2da6544f258f4b49af895e3b7abf5","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/BVXV\">$BiondVax Pharmaceuticals Ltd.(BVXV)$</a>BiondVax公布M-001通用流感疫苗候选药物3期临床试验结果https://basic.10jqka.com.cn/ajax/usaph/pubDetail/bb6a82c9419cc29f_translation?supportzoom=true&amp;client_userid=A2W2r&amp;share_hxapp=gsc&amp;share_action=&amp;back_source=hyperlink</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/BVXV\">$BiondVax Pharmaceuticals Ltd.(BVXV)$</a>BiondVax公布M-001通用流感疫苗候选药物3期临床试验结果https://basic.10jqka.com.cn/ajax/usaph/pubDetail/bb6a82c9419cc29f_translation?supportzoom=true&amp;client_userid=A2W2r&amp;share_hxapp=gsc&amp;share_action=&amp;back_source=hyperlink</body></html>","text":"$BiondVax Pharmaceuticals Ltd.(BVXV)$BiondVax公布M-001通用流感疫苗候选药物3期临床试验结果 https://basic.10jqka.com.cn/ajax/usaph/pubDetail/bb6a82c9419cc29f_translation?supportzoom=true&client_userid=A2W2r&share_hxapp=gsc&share_action=&back_source=hyperlink","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/301297613","repostId":0,"isVote":1,"tweetType":1,"viewCount":1500,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["BVXV"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":253,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":2967309,"gmtCreate":1603515266315,"gmtModify":1603517614499,"authorId":3564867055159291,"author":{"id":3564867055159291,"authorId":3564867055159291,"name":"耐思","avatar":"https://static.tigerbbs.com/e3c2da6544f258f4b49af895e3b7abf5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":301297613,"type":1,"supId":0,"prevId":0,"content":"以色列耶路撒冷-2020年10月23日-BiondVax Pharmaceuticals Ltd. （NASDAQ:BVXV）是一家开发通用流感疫苗的先驱，旨在提供针对当前、未来、季节性和大流行性流感的保护，今天公布了该公司作为独立的通用流感疫苗候选企业的关键的M-001三期临床试验的Topline数据。","text":"以色列耶路撒冷-2020年10月23日-BiondVax Pharmaceuticals Ltd. （NASDAQ:BVXV）是一家开发通用流感疫苗的先驱，旨在提供针对当前、未来、季节性和大流行性流感的保护，今天公布了该公司作为独立的通用流感疫苗候选企业的关键的M-001三期临床试验的Topline数据。","html":"以色列耶路撒冷-2020年10月23日-BiondVax Pharmaceuticals Ltd. （NASDAQ:BVXV）是一家开发通用流感疫苗的先驱，旨在提供针对当前、未来、季节性和大流行性流感的保护，今天公布了该公司作为独立的通用流感疫苗候选企业的关键的M-001三期临床试验的Topline数据。","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":2967310,"gmtCreate":1603515334898,"gmtModify":1603515334898,"authorId":3564867055159291,"author":{"id":3564867055159291,"authorId":3564867055159291,"name":"耐思","avatar":"https://static.tigerbbs.com/e3c2da6544f258f4b49af895e3b7abf5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":301297613,"type":1,"supId":0,"prevId":0,"content":"巴博科夫博士继续说， \"我们已经开发了专门知识和知识产权来实现我们的目标，我们保留了一个最先进的制造设施。今后，我们将研究各种选择，以最大限度地提高这些资产的价值。","text":"巴博科夫博士继续说， \"我们已经开发了专门知识和知识产权来实现我们的目标，我们保留了一个最先进的制造设施。今后，我们将研究各种选择，以最大限度地提高这些资产的价值。","html":"巴博科夫博士继续说， \"我们已经开发了专门知识和知识产权来实现我们的目标，我们保留了一个最先进的制造设施。今后，我们将研究各种选择，以最大限度地提高这些资产的价值。","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":2967444,"gmtCreate":1603528725580,"gmtModify":1603528725580,"authorId":3492254180145135,"author":{"id":3492254180145135,"authorId":3492254180145135,"name":"稳之道","avatar":"https://static.tigerbbs.com/7aa851d5fc818b68d914f96366d8d9e7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":301297613,"type":1,"supId":0,"prevId":0,"content":"已阅知，稳住就是","text":"已阅知，稳住就是","html":"已阅知，稳住就是","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/301297613"}